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CASE REPORT
Transient Hemolytic An.emia after Transju,gular
Intrahepatic Portosystemic Stent Shunt
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Management of variceal bleeding secondary to portal hypertension constitutes a challenging issue, particu-
larly in child’s C cirrhotic patients. Recently, transjugular placement of self-expanding metallic stents in the
liver (TIPS), creating a shunt between the portal and hepatic branches has provided a safe and promising
therapeutic approach in this clinical situation. We report here the case ofa 66-year-old male cirrhotic patient
who developed a moderately severe clinical picture of a Coombsnegative hemolytic anemia (serum
hemoglobin, 93 g/l, serum bilirubin 160.74 umol/L (9.4 mg/dl), indirect 6.3 mg/dl (107.73 umol/L); serum
LDH 1220 u/l, reticulocytes, 5.1%. serum ferritin, 1221 ug/1, schistocytes in peripheral blood smear) the week
after undergoing a TIPS, suggesting the development ofa microangiopathic hemolytic anaemia secondary to
red blood cell disruption by passing through the metallic network of the stent.
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INTRODUCTION
Variceal bleeding is a major complication of cirrhotic
patients, associated with high mortality rates. Several
therapeutic approaches are currently available, including
pharmacological management with somatostatin and/or
vasopressin, balloon tamponade, sclerotherapy, embo-
lization, and porto systemic shunt 1, this last being asso-
ciated with the lowest rate of rebleeding 2. However,
emergency shunt operations are usually reserved for
patientsinwhom other therapies have been ineffective,
mortality rates reaching figures as high as 50% among
Child’s C cirrhotics who undergo this intervention 3.
In recent times, self-expanding metallic stents have
been placed in the liver, creating a shunt between the
portal and hepatic branches (transjugular intrahe-
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patic portosystemic shunt, TIPS), thus providing a
promising approach for these clinical situations 4-9.
We report here the case of a patient who developed a
moderately severe, transient clinical picture of
hemolytic anemia after undergoing a TIPS, a compli-
cation not reported before, except perhaps for another
case in which persistent hemolysis and encephalopathy
developed 10.
CASE REPORT
A 66-years-old male patient was referred to our hospi-
tal in order to undergo a TIPS. He had been treated in
another center and liver cirrhosis had been diagnosed.
He denied alcoholic intake, and there was a history of
past blood transfusions in the course of a
theracoplasty. Antibodies to hepatitis C virus were
positive. In the last 4 months he had presented with
eight episodes of variceal bleeding, treated with
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sclerotherapy and/or balloon tamponade together
with pharmacological measures and blood transfu-
sions. During his stay in that hospital, serum bilirubin,
although slightly elevated at admission (42.75
umol/1), dropped to normal values afterwards.
Prothrombin activity was 50%, and the patient devel-
oped ascites. A new bleeding episode due to variceal
rupture, 24 hours after a sclerotherapy session lead his
doctors to send him to our hospital.
At admission to our hospital a TIPS was performed,
placing a 46 mm long metallic stent between the right
hepatic vein and the portal system. However, this
procedure neither caused a normalization of portal
pressure, nor stopped variceal bleeding-the patient
received another transfusion-, so another stent, 75mm
lenght, was inserted 5 days later, using techniques
already described 6.
Bleeding immediately stopped after placement of
this second device, portal pressure dropping from 36
to 17 cm H20. In the following days, however, serum
bilirubin progressively increased (from 58.14 umoI/L
to 160.74 umol/L), indirect (107.73 umol/L) (Fig. 1),
hemoglobin fluctuating between 90 and 91 g/1. This
elevation in serum bilirubin was accompanied by an
elevation in serum LDH (fig 1), reaching maximum
levels of 1210 U/1; Coombs test was negative, serum
ferritin reached 1221 ug/1, and haptogolobin was
undetectable. Schistocytes were observed in the
peripheral blood smear. Reticulocytes increased
markedly, (153.000/mm3, 5.1%). A week later, bilirubin
dropped (71.82 umol/L (4.2 mg/dl), indirect 35.96
umol/L (2.1 md/dl)) and later the, jaundice disap-
peared, total bilirubin dropping to 42.75 umol/L, se-
rum LDH, to 645 U/l, and hemoglobin raising to 124
g/1. Ascites also disappeared and the patient did not
present any sign of encephalopathy. No rebleeding
has been observed.
DISCUSSION
Transjugular installation of intrahepatic self-expanding
metallic stents seems to constitute an excellent alterna-
tive to surgical portocaval shunts. Although some major
complications-including death-have been described 8,10,
majorproblems are thrombosis and stenosis ofthe artifi-
cially-created shunts, although followup portography
and radilation by further angioplasty may prevent these
complications 7. Indeed, after placement of the metallic
device a neointima gradually develops, and sometimes it
contributes to stenosis and thrombosis ofthe stent. How-
ever, before the intima grows, blood cells are forced
through the metallic network, the possibility existing of
red blood cell rupture leading to variable degrees of
microangiopathic hemolytic anemia.We believe that our
patient developed such a clinical picture. Although he
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Figure 1 Variation in serum bilirubin (BRBT=total bilirubin; BRBI indirect bilirubin) and LDH levels.TIPS AND HEMOLYSIS 251
received transfusions during the stay in the other hospi-
tal, serum bilirubin was normal at that time; although he
also received a transfusion before the second TIPS was
performed, the rise in serum bilirubin was marked and
reached its maximum not in the first days, but one week
later. Recovery ofthis situation occurred spontaneously,
patient is asymptomatic, withoutjaundice and with nor-
mal bilirubin values. Perhaps, recovery of hemolysis is
concomitant with the development ofa neointima which
partially covers even the free portions of the metallic
network and therefore diminishes red blood cell rupture.
In another case described, hemolysis was persistent, only
subsiding after liver transplantation and removal of the
Wallstent 10; itwas supposed that blood flow through the
wire mesh of the free portion of the stent caused
intravascular hemolysis.
Thus, our case illustrates a rarely described but
expectable complication of TIPS, i.e., a transient
microangiopathic hemolytic anemia probably due to
red blood cell rupture by passing through the metallic
network of the intrahepatic stent.
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